Publications

PUBLICATIONS

MiraKind is working to further identify ways to preserve health and prevent cancer for individuals with the KRAS-variant and other genetic variants like it.

2025

Schulz-Jaavall MB, Kishan AU, Dang A, Telesca D, Lilleby WA, Weidhaas JB  
Radiother Oncol. 2024;187:109090
Kishan AU, McGreevy K, Valle L, Steinberg M, Neilsen B, Casado M, Cao M, Telesca D, Weidhaas JB  
Clin Cancer Res. Jun 13, 2025;31(12):2530–2538
Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Ryg U, Schulz-Jaavall MB, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter RE, Rettig MB, Steinberg ML, Sisk A, Brisbane W, Marks LS, Boutros PC, Lilleby WH, Kishan AU  
Radiother Oncol. May 2, 2025;206:S2146
Kishan AU, Marco N, Schulz-Jaavall MB, Steinberg M, Neilsen B, Casado M, Cao M, Telesca D, Weidhaas JB  
Cancer Res. 2025;85(1 Suppl):Abstract 1234
Kishan AU, Dang A, Schulz-Jaavall MB, Steinberg M, Weidhaas JB  
Radiother Oncol. 2025;188:109204
Schulz-Jaavall MB, Kishan AU, Dang A, Lilleby WA, Weidhaas JB  
Cancer Res. 2025;85(8 Suppl):Abstract 4567
Calais J, Kishan AU, Valle LF, Wilhalme H, Dang A, Telesca D, Schulz-Jaavall MB, Lilleby WA, Weidhaas JB  
J Clin Oncol. Oct 2025;43(15_suppl):LBA90
Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall MB, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter RE, Rettig MB, Steinberg ML, Sisk A, Brisbane W, Marks LS, Boutros PC, Lilleby WH, Kishan AU  
Int J Radiat Oncol Biol Phys. Sep 2025;124(1):S53
Calais J, Kishan AU, Valle LF, Wilhalme H, Dang A, Telesca D, Schulz-Jaavall MB, Lilleby WA, Weidhaas JB  
J Clin Oncol. Dec 2025;43(34_suppl):LBA5000
Smith CP, Kishan AU, Raldow AC, Telesca D, Lilleby WA, Weidhaas JB  
Cancer Res. 2025;85(14 Suppl):Abstract 2987
Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall MB, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter RE, Rettig MB, Steinberg ML, Sisk A, Brisbane W, Marks LS, Boutros PC, Lilleby WH, Kishan AU  
Int J Radiat Oncol Biol Phys. Sep 2025;124(1):S53
Schulz-Jaavall MB, Kishan AU, Dang A, Lilleby WA, Weidhaas JB  
Radiother Oncol. 2025;189:110013
Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J  
J Clin Oncol. Nov 12, 2025;43(15_suppl):LBA90. doi:10.1200/JCO-25-01553. PMID: 41223345
Schulz-Jaavall MB, Kishan AU, Dang A, Lilleby WA, Weidhaas JB  
Cancer Res. 2023;83(8 Suppl):Abstract 2986
Schulz-Jaavall MB, Kishan AU, Dang A, Lilleby WA, Weidhaas JB  
Cancer Res. 2023;83(16 Suppl):Abstract PROSTOX
Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU  
Eur Urol Oncol. Mar 2023;6(2):224–227
Schulz-Jaavall MB, Kishan AU, Dang A, Brenman ND, Telesca D, Lilleby WA, Weidhaas JB  
Cancer Res. 2023;83(8 Suppl):Abstract 2815
Weidhaas JB, Kishan AU, Dang A, Telesca D, Lilleby WA, Schulz-Jaavall MB  
Int J Radiat Oncol Biol Phys. 2023;117(4 Suppl):E525
Li Z, Raldow AC, Weidhaas JB, Qi X, et al.  
Cancers. Oct 2023;15(21):5142

2021

Association between rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene and breast cancer risk in a Mexican population
M P Gallegos-Arreola, P M García Verdín, M T Magaña-Torres, L E Figuera, G M Zúñiga-González, M A Rosales-Reynoso, B C Gómez-Meda, A M Puebla-Pérez Eur Rev Med Pharmacol Sci. 20Nov;25(21):6454-6464. PMID: 34787849

Rosenthal ST, Weidhaas JB  
Career Development in Academic Radiation Oncology. May 2021;343–359

2020

Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population
Neda Farokhzad, Sayed Mostafa Hosseini, Houri Edalat, Morteza Sadeghi
Afr Health Sci. 2020 Sep;20(3):1299-1303. PMID: 33402978

Weidhaas JB  
Methods Mol Biol. 2020;2055:203–212
Rakowski Pérez M, Wang-Gohrke S, Weidhaas JB, Slack FJ  
Prostate. Jun 1, 2020;80(8):732–740
Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, Dry SM, Nelson SD, Hernandez J, Chmielowski B, Singh AS, Bukata SV, Bernthal NM, Steinberg ML, Weidhaas JB, Eilber FC  
Clin Cancer Res. Feb 13, 2020;26(8):1829–1836
Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB  
Eur Urol. Sep 2020;78(3):327–332
Ma SJ, Kishan AU, Schipper MJ, Ng A, Feng Z, Lee C, Weidhaas JB, Spiotto MT, Levy LB, Mahal BA, Zelefsky MJ  
Radiother Oncol. Oct 2020;150:112–118. doi:10.1016/j.radonc.2020.07.022

2019

MicroRNA-binding site polymorphisms and risk of colorectal cancer: A systematic review and meta-analysis
Morteza Gholami, Bagher Larijani, Farshad Sharifi, Shirin Hasani-Ranjbar, Reza Taslimi, Milad Bastami, Rasha Atlasi, Mahsa M Amoli, Cancer Med. 2019 Dec;8(17):7477-7499. doi: 10.1002/cam4.2600. PMID: 31637880

Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study
Thomas M D'Hooghe, Olga Grechukhina, SiHyun Cho, Amelie Fassbender, Dorien O, Daniëlle Peterse, Joanne Weidhaas, Hugh S Taylor, Gynecol Obstet Invest. 2019;84(6):575-582. doi:10.1159/000500626. Epub 2019 Jun 11 PMID: 31185482

Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers
Vianney Bastit, Nicolas Bon-Mardion, Jean-Michel Picquenot, Vinciane Rainville, Cristian Moldovan, Arnaud François, Agnès Loeb, Sébastien Thureau, Dorel Manu, Fabrice Jardin, Jean-Paul Marie, Fréderic Di Fiore, Florian Clatot
Eur Arch Otorhinolaryngol. 2019 Feb;276(2):541-550. doi: 10.1007/s00405-018-5235-6. PMID: 30523411

Weidhaas JB, Marco N, Scheffler AW, Kalbasi A, Wilenius K, Rietdorf E, Gill J, Heilig M, Desler C, Chin RK, Kaprealian T, McCloskey S, Raldow A, Raja NP, Kesari S, Carrillo J, Drakaki A, Scholz M, Telesca D  
J Immunother Cancer. Feb 2022;10(2):e003625
Weidhaas JB, Paranjape T, Slack FJ  
Breast Cancer Res Treat. Sep 2019;178(2):249–259
Jung SY, Malhotra P, Nguyen KC, Salzman D, Qi Y, Pak EH, King J, Vlashi E, Ann D, Weidhaas JB  
Cell Death Differ. Apr 1, 2019;26(12):2568–2576. doi:10.1038/s41418-019-0320-y

2017

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis
E K Morgen, H-J Lenz, D J Jonker, D Tu, G Milano, F Graziano, J Zalcberg, C S Karapetis, A Dobrovic, C J O'Callaghan, G Liu
Pharmacogenomics J. 2017 Dec;17(6):535-542. doi: 10.1038/tpj.2016.56. PMID: 27897268

KRAS Gene Polymorphisms and their Impact on Breast Cancer Risk in an Iranian Population
Sanaei S, Hashemi M, Eskandari E, Hashemi SM, Bahari G.
Asian Pac J Cancer Prev. 2017 May 1;18(5):1301-1305.
PMID: 28610418

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478. PMID: 28006059

2016

A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
Kazmi HR, Chandra A, Kumar S, Satyam LK, Gupta A, Nigam J, Srivastava M, Mittal B.
J Cancer Res Clin Oncol. 2016 Sep 12.

Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J, Seijas-Tamayo R, Mesía R, Taberna M, Pastor Borgoñón M, Pérez-Ruiz E, Adansa Klain JC, Vázquez Fernández S, Del Barco Morillo E, Lozano A, González Sarmiento R, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).
Oral Oncol. 2016 Dec;63:38-43. doi: 10.1016/j.oraloncology.2016.10.006. Epub 2016 Nov 12. PMID: 27938998

A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells. 
Zhang S1, Hou C1, Li G1, Zhong Y1, Zhang J1, Guo X1, Li B2, Bi Z1, Shao M1.1., Int J Mol Med. 2016 Sep;38(3):919-26. doi: 10.3892/ijmm.2016.2661. Epub 2016 Jul 4.

The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.
Gutiérrez-Malacatt H, Ayala-Sanchez M, Aquino-Ortega X, Dominguez-Rodriguez J, Martinez-Tovar A, Olarte-Carrillo I, Martinez-Hernandez A, C CC, Orozco L, Cordova EJ. Asian Pac J Cancer Prev. 2016;17(4):2265-70. PMID: 27221928, Free Article, Similar articles, Select item 26710843

KRAS polymorphisms are associated with survival of CRC in Chinese population.
Dai Q, Wei HL, Huang J, Zhou TJ, Chai L, Yang ZH., Tumour Biol. 2016 Apr;37(4):4727-34. doi: 10.1007/s13277-015-4314-1. Epub 2015 Oct 29., PMID: 26515332, Similar articles, Select item 26162609

Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas JB, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LFAG, Kiemeney LA, Aben KKH, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB  
Nat Genet. Oct 19, 2010;42(10):880–884
Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ  
Oncogene. Jan 26, 2017;36(4):512–524

2015

Impact of KRAS variant rs61764370 on breast cancer morbidity.
Ustinova M, Daneberga Z, Bērziņa D, Nakazawa-Miklaševiča M, Maksimenko J, Gardovskis J, Miklaševičs E., Exp Oncol. 2015 Dec;37(4):292-4., PMID: 26710843, Similar articles, Select item 26573509

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Fabbri MA, Martelli O, Fagnani D, Locatelli MC, Bertolini A, Valmadre G, Pavese I, Calcagno A, Sarobba MG, Marabese M., Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331., PMID: 26573509, Free PMC Article, Similar articles Select item 26515332

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N., Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10., PMID: 26162609, Similar articles, Select item 26077004

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M, Simova J, Kubova B, Dvorackova N, Tomaskova H, Sedivcova M, Dite P., Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):466-71. doi: 10.5507/bp.2015.029. Epub 2015 Jun 11., PMID: 26077004, Free Article, Similar articles, Select item 25987236

Functional variants in CYP1B1, KRAS and MTHFR genes are associated with shorter telomere length in postmenopausal women.
Cerne JZ, Pohar-Perme M, Cerkovnik P, Gersak K, Novakovic S., Mech Ageing Dev. 2015 Jul;149:1-7. doi: 10.1016/j.mad.2015.05.003. Epub 2015 May 15., PMID: 2598723, Similar articles, Select item 25940428

Estrogen Withdrawal, Increased Breast Cancer Risk and the KRAS-variant.
McVeigh TP et al. Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11. PMID: 25961464  Free PMC Article Similar articles Select item 25940428

Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
Farahani MS, Shahbazi S, Moghaddam SA, Mahdian R., Reprod Sci. 2015 Jun;22(6):679-84. doi: 10.1177/1933719114556478. Epub 2014 Oct 30., PMID: 25361550, Free PMC Article, Similar articles, Select item 25183481

Ratner E, Slack FJ, Weidhaas JB, Paranjape T, Zheng T, Hoffman AE, Zhang Y  
Endocr Relat Cancer. Mar 1, 2019;26(3):181–190. doi:10.1530/ERC-18-0407. PMID: 30712587

2014

The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J., PLoS One. 2014 Apr 14;9(4):e94167. doi: 10.1371/journal.pone.0094167. eCollection 2014., PMID: 24732316 Free PMC Article, Similar articles, Select item 23083368

The involvement of KRAS gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.
Ying HQ, Wang F, He BS, Pan YQ, Gao TY, Xu YQ, Li R, Deng QW, Sun HL, Wang SK., Onco Targets Ther. 2014 Aug 25;7:1487-96. doi: 10.2147/OTT.S65496. eCollection 2014., PMID: 25210463 Free PMC Article, Similar articles, Select item 25183481

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S., Clin Cancer Res. 2014 Sep 1;20(17):4499-510. doi: 10.1158/1078-0432.CCR-14-0348., PMID: 25183481 Free PMC Article, Similar articles, Select item 2511458

MicroRNA binding site polymorphisms as biomarkers in cancer management and research.
Cipollini M, Landi S, Gemignani F., Pharmgenomics Pers Med. 2014 Jul 23;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014. Review., PMID: 25114582, Free PMC Article, Similar articles, Select item 25081901

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH et al. Ann Oncol. 2014 Nov;25(11):2230-6. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31.

A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
De Ruyck K, Duprez F, Ferdinande L, Mbah C, Rios-Velazquez E, Hoebers F, Praet M, Deron P, Bonte K, Speel EJ, Libbrecht L, De Neve W, Lambin P, Thierens H., Cancer Epidemiol. 2014 Oct;38(5):591-8. doi: 10.1016/j.canep.2014.07.008. Epub 2014 Aug 12., PMID: 25127693, Similar articles, Select item 24932237

SLC23A2-05 (rs4987219) and KRAS-LCS6 (rs61764370) polymorphisms in patients with squamous cell carcinoma of the head and neck.
Santiago MB, DE Lima Marson FA, Secolin R, Ribeiro JD, Lima CS, Bertuzzo CS., Oncol Lett. 2014 Jun;7(6):1803-1811. Epub 2014 Apr 3., PMID: 24932237 Free PMC Article, Similar articles, Select item 24890702

Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM, Christensen BC., Cancer Med. 2014 Oct;3(5):1385-95. doi: 10.1002/cam4.279. Epub 2014 Jun 2. Review., PMID: 24890702 Free PMC Article, Similar articles, Select item 24282149

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB., Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11., PMID: 24727325 Free PMC Article, Similar articles, Select item 23324806

Ratner E, Malila N, Weidhaas JB, Slack FJ  
Cancer Genet. 2014 Aug;207(8-9):347–352. doi:10.1016/j.cancergen.2014.09.006. PMID: 25219036
Weidhaas JB, Ratner E, Nallur S, Unger S, Babar I, Slack FJ, Paranjape T  
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1047–1055. doi:10.1016/j.ijrobp.2013.11.023. PMID: 24559601
Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas JB, Small W Jr  
Int J Gynecol Cancer. Jun 1, 2014;24(5):956–962. doi:10.1097/IGC.0000000000000135. PMID: 24819663
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH  
JAMA Oncol. Apr 1, 2017;3(4):483–491. doi:10.1001/jamaoncol.2016.5478
Weidhaas JB, Kim E, Herbst RS, Yu J, Slack FJ, et al.  
J Clin Oncol. May 2014;32(15_suppl):8135
Zhang Y, Zheng T, Hoffman AE, Paranjape T, Weidhaas JB, Slack FJ, Leaderer D  
Cancer Prev Res (Phila). Aug 2014;7(8):783–792. doi:10.1158/1940-6207.CAPR-14-0065. PMID: 24821729
Paranjape T, Zheng T, Slack FJ, Weidhaas JB, Zhang Y  
Breast Cancer Res Treat. Jul 2015;152(1):123–131. doi:10.1007/s10549-015-3455-4. PMID: 26182052
Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB  
Ann Oncol. Nov 1, 2014;25(11):2230–2236. doi:10.1093/annonc/mdu367. PMID: 25081901
Staudacher JJ, Ratner E, Ghosh D, Fries W, Boige V, Haller DG, Weidhaas JB, Slack FJ  
Cancer. Jan 15, 2015;121(2):206–214. doi:10.1002/cncr.29095. PMID: 25393542

2013

Targeted Knock-in of the Polymorphism rs61764370 does not Affect KRAS Expression but Reduces let-7  Levels
Crowley EH et al. Hum Mutat. 2013 Nov 26.

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients
Sebio A et al. Pharmacogenet Genomics. 2013 Mar;23(3):142-7.

Kunos C, Winter K, Dicker AP, Small W Jr, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB, Gaffney DK  
Int J Radiat Oncol Biol Phys. Jun 15, 2013;86(3):420–427. doi:10.1016/j.ijrobp.2012.12.018. PMID: 23485551
Pelletier C, Weidhaas JB  
Nat Rev Clin Oncol. Sep 2013;10(9):552–564. doi:10.1038/nrclinonc.2013.114. PMID: 23817382
Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB  
Ann Oncol. Nov 2014;25(11):2230–2236. doi:10.1093/annonc/mdu367. PMID: 25081901
Ahmad A, Ahmad S, Weidhaas JB, Hui P, Santin A, Azodi M, Silasi D, Schwartz P, Rutherford T, Ratner E  
Gynecol Oncol. Jul 2013;130(1):e92. doi:10.1016/j.ygyno.2013.04.274
Kong KL, Kwong DLW, Chan THM, Law S, Tsang CM, Ho KY, Bruce JP, Lung ML, Weidhaas JB  
Int J Cancer. Sep 15, 2013;133(6):1409–1416. doi:10.1002/ijc.28201. PMID: 23494964
Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M  
Int J Radiat Oncol Biol Phys. Jan 1, 2014;88(1):11–17. doi:10.1016/j.ijrobp.2013.09.040. PMID: 24246724

2012

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH., BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534., PMID: 23167843 Free PMC Article, Similar articles, Select item 23010532

No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
Luong HT, Nyholt DR, Painter JN, Chapman B, Kennedy S, Treloar SA, Zondervan KT, Montgomery GW., Hum Reprod. 2012 Dec;27(12):3616-21. doi: 10.1093/humrep/des329. Epub 2012 Sep 25., PMID: 23010532 Free PMC Article, Similar articles, Select item 22679560

KRAS-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M., Am J Cancer Res. 2012;2(3):298-308. Epub 2012 Apr 21., PMID: 22679560 Free PMC Article, Similar articles, Select item 22662244

KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter
Ryan BM, et al. Clin Cancer Res. 2012 Jun 15;18(12):3487-8; author reply 3489.

A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis
Grechukhina O., et al. EMBO Mol Med. 2012 Mar;4(3):206-17.

High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease
Ruzzo A et al. Oncologist. 2012;17(6):823-9.

SNPing cancer in the bud: MicroRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer
Salzman & Weidhaas., Pharmacol Therapy, 2012.

KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study
Cerne et al., BMC Cancer, 2012.

The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer
Pilarski et al., PLoS One, 2012.

KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel
Kundu ST et al. Cell Cycle. 2012 Jan 15;11(2):361-6.

Ratner E, Nallur S, Paranjape T, Weidhaas JB, Slack FJ  
Cancer Res. 2013;73(8 Suppl):P1-09-05. doi:10.1158/1538-7445.AM2013-P1-09-05
Kunos C, Winter K, Dicker AP, Small W Jr, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB, Gaffney DK  
Gynecol Oncol. Mar 2012;125(1):S44–S45. doi:10.1016/j.ygyno.2011.12.104
Ratner E, Giese R, Nallur S, Fathy H, Weidhaas JB, Reid-Lombardo KM, Kuo J, Shapiro M, Cramer DW, Missmer SA, Montgomery BE, Scholtens DM  
Mol Hum Reprod. Dec 2011;17(12):747–751. doi:10.1093/molehr/gar076. PMID: 21859997
Ratner E, Tassi RA, Richmond RC, Nallur S, Weidhaas JB, Slack FJ  
Cancer. 2012 May 1;118(9):2713–2721. doi:10.1002/cncr.26454. PMID: 22275314
Moran MS, Ma S, Jagsi R, Yang TI, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S  
Int J Radiat Oncol Biol Phys. 2013 Jan;85(1):40–46. doi:10.1016/j.ijrobp.2012.03.025. PMID: 22658441
Zavala E, Dismuke D, Weidhaas JB, et al.  
Blood. 2012 Nov 15;120(20):S67. doi:10.1182/blood.V120.21.67.67
Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M  
Clin Cancer Res. Dec 15, 2011;17(24):7723–7731. doi:10.1158/1078-0432.CCR-11-0990. PMID: 21994416
Salzman DW, Weidhaas JB  
Pharmacol Ther. Jan 2013;137(1):55–63. doi:10.1016/j.pharmthera.2012.08.016. PMID: 22964086
Doll CM, Winter K, Gaffney DK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM  
Int J Radiat Oncol Biol Phys. Apr 1, 2013;85(5):1312–1318. doi:10.1016/j.ijrobp.2012.12.011. PMID: 23433910

2011

A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer
Ratner E. et al. Oncogene. 2011 Dec. 5.

A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer
Kim M. Smits et al. Clin Cancer Research, 2011, Oct 12.

MicroRNA signatures differentiate melanoma subtypes
Chan E. et al. Cell Cycle. 2011 Jun1:10(11):1845-52.

KRAS rs61764370 in Epithelial Ovarian Cancer-Letter
Joanne B. Weidhaas and Frank J. Slack. Clinical Cancer Research. Accepted May 31, 2011.

A 3’ untranslated region KRAS variant and triple-negative breast cancer: a case control and genetic analysis
Paranjape T. et al. Lancet Oncology. 2011 Apr;12(4):377-86.

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D; BCFR Investigators, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D; EMBRACE Investigators, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O; GEMO Study Collaborators, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M; HEBON Investigators, Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G; kConFab Investigators and the Consortium of Investigators of Modifiers of BRCA1/2, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A; SWE-BRCA Investigators, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA; Ovarian Cancer Association Consortium., Clin Cancer Res. 2011 Jun 1;17(11):3742-50. doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8., PMID: 21385923 Free PMC Article, Similar articles, Select item 20676756

KRAS Let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?
Zhang W. et al. Ann Oncol. 2011 Feb 22(2):484-5.

Marsh C, Weidhaas JB, Slack FJ, Paranjape T, Zheng T, Hoffman AE, Zhang Y, Leaderer D  
Breast Cancer Res Treat. 2011 Nov;130(2):449–459. doi:10.1007/s10549-011-1560-6. PMID: 21487933
Morse DL, Weidhaas JB, Ratner E, Nallur S, Slack FJ, Paranjape T, Zheng T, Hoffman AE, Zhang Y, Leaderer D  
Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):555–567. doi:10.1158/1055-9965.EPI-11-0766. PMID: 22215876
Ratner E, Nallur S, Weidhaas JB, Slack FJ, Lu L, Boeke M, Barnett R  
Cancer Res. 2012;72(24 Suppl):Abstract 3029. doi:10.1158/0008-5472.CAN-12-3029
Slack FJ, Weidhaas JB  
Am J Pathol. 2012 Jul;181(2):360–372. doi:10.1016/j.ajpath.2012.04.001. PMID: 22705342
Ratner E, Lu L, Nallur S, Slack FJ, Weidhaas JB, Boeke M, Barnett R  
Cancer. 2012 Oct 1;118(19):4810–4816. doi:10.1002/cncr.27478. PMID: 22718288
Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ  
Mol Ther. Jun 22, 2011;19(6):1116–1122. doi:10.1038/mt.2011.48. PMID: 21427705
Weidhaas JB, Kirsch DG  
Int J Radiat Oncol Biol Phys. Jun 1, 2011;80(2):321–323. doi:10.1016/j.ijrobp.2011.01.030. PMID: 21549248
Ng AK, Mauch PM, Donaldson SS, Garber JE, Weidhaas JB, Rosenberg SA, Abramson DH, Packer RJ, Constine LS, Hoppe RT, Yahalom J  
J Clin Oncol. Aug 10, 2011;29(23): 3027–3034. doi:10.1200/JCO.2011.35.3486. PMID: 21747040
Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee J, Nieuwlaat A, Dorssers LCJ, Seynaeve C, Aulchenko YS, Martens JWM, van den Ouweland AMW, Weidhaas JB  
Breast Cancer Res Treat. Jul 2011;128(1):79–84. doi:10.1007/s10549-010-1080-z. PMID: 20676756
Kulkarni-Paranjape T, Nallur S, Weidhaas JB  
Cancer Res. 2013;73(8 Suppl):Abstract 5061. doi:10.1158/1538-7445.AM2013-5061
Slack FJ, Weidhaas JB  
Cancer Res. 2011 Nov 1;71(21):6421–6425. doi:10.1158/0008-5472.CAN-11-2647. PMID: 22056906
Hansen JE, Reza F, Nallur S, Weidhaas JB, Dorssers LCJ  
Int J Radiat Oncol Biol Phys. Oct 1, 2011;81(2):S21–S22. doi:10.1016/j.ijrobp.2011.06.866
Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ  
Cancer Biol Ther. Oct 1, 2011;12(10):908–914. doi:10.4161/cbt.12.10.17681. PMID: 22027557
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller R-U, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB  
Oncogene. Dec 5, 2011;31(42):4559–4566. doi:10.1038/onc.2011.539. PMID: 22139083
Zhang W, Ratner E, Danenberg KD, Danenberg PV, Lenz H-J, Weidhaas JB, Slack FJ, Tsao-Wei DD, Groshen S, Danenberg K  
Clin Cancer Res. Jan 15, 2012;18(2):485–491. doi:10.1158/1078-0432.CCR-11-2372. PMID: 22106272

2010

Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
Graziano F et al. Pharmacogenomics J. 2010 Oct;10(5):458-64.

Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients
Ruzzo A et al. Ann Oncol. 2010 Oct 6.

KRAS Mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer
Nelson HH et al. Lung Cancer. 2010 Jul;69(1).

A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy
Zhang W et al. Ann Oncol. 2010 Jul 5.

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk
Ratner E et al. Cancer Res. 2010 Aug 15;70(16):6509-15.

Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
Hollestelle A et al. Breast Cancer Res Treat. 2011 Jul 30.

The KRAS-Variant Genetic Test As a Marker of Increased Risk of Ovarian Cancer
Keane FK and Ratner ES. Rev Obstet Gynecol. 2010 Summer;3(3):118-21.

Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Euhus D, O’Connell P, Weidhaas JB, Slack FJ  
Cancer Res. 2011 Jan 1;71(1):111–117. doi:10.1158/0008-5472.CAN-10-2130. PMID: 21151174
Pelletier C, Weidhaas JB  
Expert Rev Mol Diagn. 2011 Nov;11(6):817–829. doi:10.1586/erm.11.61. PMID: 22017563
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Euhus D, O’Connell P, Weidhaas JB, Slack FJ  
Cancer Res. 2011;71(24 Suppl):Abstract O-43. doi:10.1158/0008-5472.CAN-11-O43
Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas JB, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown RS, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LFAG, Kiemeney LA, Aben KKH, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB  
Nat Genet. 2010 Oct;42(10):880–884. doi:10.1038/ng.666. PMID: 20852633
Ratner E, Sebastiani P, Nallur S, Taylor M, Weidhaas JB, Slack FJ  
Cancer. 2011 Jul 15;117(14):3260–3266. doi:10.1002/cncr.25903. PMID: 21509841
Weidhaas JB, Ratner E, Nallur S, Unger S, Babar I, Slack FJ  
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1954–1961. doi:10.1016/j.ijrobp.2011.12.058. PMID: 22248955
Blitzblau RC, Weidhaas JB  
Mol Diagn Ther. Dec 1, 2010;14(6):335–342. doi:10.1007/BF03256390. PMID: 21275451

2009

A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers
Christensen BC et al. Carcinogenesis. 2009 Jun;30(6):1003-7.

Higgins SA, Weidhaas JB, Black D, Martel M, Christy CJ, Harris L, Miller KD, Lannin DR  
Ann Surg Oncol. 2009 Jul;16(7):1915–1922. doi:10.1245/s10434-009-0453-7. PMID: 19357849
Kulkarni-Paranjape T, Nallur S, Keanie K, Martel M, Weidhaas JB  
Cancer Res. 2009 Feb;69(2 Suppl):Abstract 2040. doi:10.1158/0008-5472.SABCS-2040
Elkin EB, Gonzales AR, Ishill NM, Klem ML, Hodgson DC, Ng AK, Marks LB, Weidhaas JB, Freedman GM, Miller RC, et al.  
J Clin Oncol. 2009 May;27(15_suppl):607. doi:10.1200/JCO.2009.27.15_suppl.607
Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yaffe MB, Weidhaas JB, Beer DG, Maitra A, Croce CM  
Nature. 2007 Apr 19;447(7149):1128–1132. doi:10.1038/nature05939. PMID: 17554389
Weidhaas JB, Li SX, Winter K, Ryu J, Jhingran A, Miller B, Dicker AP, Gaffney D  
Clin Cancer Res. 2009 Jun 15;15(12):4199–4206. doi:10.1158/1078-0432.CCR-08-2257. PMID: 19509178
Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas JB, Slack F, Zhang Y, Paranjape T, Zhu Y  
Cancer Res. 2009 Jul 15;69(14):5970–5977. doi:10.1158/0008-5472.CAN-09-0236. PMID: 19567675
Kulkarni-Paranjape T, Slack FJ, Weidhaas JB  
Gut. 2009 Nov;58(11):1546–1554. doi:10.1136/gut.2009.179531. PMID: 19834118
Doll CM, Winter K, Gaffney DK, Ryu JK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM  
Int J Radiat Oncol Biol Phys. 2009;75(3):S150. doi:10.1016/j.ijrobp.2009.08.103
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ  
Oncogene. 2010;29(11):1580–1587. doi:10.1038/onc.2009.445. PMID: 19966857
Slack FJ, Weidhaas JB  
Nat Rev Cancer. 2010 Jul;10(7):578–582. doi:10.1038/nrc2883. PMID: 20631706

2008

A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk
Chin LJ, Ratner E et al Cancer Res. 2008 Oct 15;68(20):8535-40.

Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ  
J Pathol. 2008 Nov;214(4):360–368. doi:10.1002/path.2289. PMID: 18836592
Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, DiGiovanna MP, Chung G, Abu-Khalaf M, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR  
Arch Surg. 2008 Jul;143(7):692–699. doi:10.1001/archsurg.143.7.692. PMID: 18645113
Higgins SA, Weidhaas JB, Black D, Christy CJ, Martel M, Harris L, Miller KD, Lannin DR  
Int J Radiat Oncol Biol Phys. 2009 Apr 1;74(5):1371–1377. doi:10.1016/j.ijrobp.2008.09.006. PMID: 19064292
Higgins SA, Weidhaas JB, Black D, Christy CJ, Martel M, Harris L, Miller KD, Lannin DR  
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):37–44. doi:10.1016/j.ijrobp.2009.01.045. PMID: 19345209
Weidhaas JB, Higgins SA, Black D, Christy CJ, Martel M, Harris L, Miller KD, Lannin DR  
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):540–547. doi:10.1016/j.ijrobp.2009.02.008. PMID: 19345094
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK  
Cancer Res. 2008 Oct 15;68(20):8535–8540. doi:10.1158/0008-5472.CAN-08-2129. PMID: 18922928
Slack FJ, Weidhaas JB  
Drug Dev Res. 2010;71(9):763–775. doi:10.1002/ddr.20368. PMID: 20836247

2007

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D  
J Clin Oncol. 2006 Dec 20;24(36):5652–5657. doi:10.1200/JCO.2006.06.5664. PMID: 17116942
Weidhaas JB, Slack F, Babar I, Nallur S  
Int J Radiat Oncol Biol Phys. 2007 Nov;69(3):846–854. doi:10.1016/j.ijrobp.2007.07.2411. PMID: 18054686
Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ  
Cancer Res. 2007 Dec 1;67(23):11111–11116. doi:10.1158/0008-5472.CAN-07-2858. PMID: 18056433

2006

Slack F, Weidhaas JB
Future Oncol. 2006;2(1):73–82. doi:10.2217/14796694.2.1.73. PMID: 16556074
Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9946–9951. doi:10.1073/pnas.0603791103. PMID: 16788064
Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV  
Cancer Res. 2006 Nov 1;66(21):10434–10438. doi:10.1158/0008-5472.CAN-06-2182. PMID: 17079464

2000

Relationship between retroviral DNA integration and gene expression
Weidhaas JB, Angelichio EL, Fenner S, Coffin JM
J Virol. Sep 2000;74(18):8382–8389

1997

Weidhaas JB  
Ph.D. Thesis, Tufts University, Department of Molecular Biology and Microbiology. 1997.
bottom-up-left-heavy-curve

about MiraKind

MiraKind is a 501(c)(3) non-profit organization in Los Angeles, CA.
All donations are tax-deductible.
EIN 46-4451492.

education

testing information

research

our research

studies

hormones, the KRAS-variant and breast cancer risk study

publications

get involved

subscribe to our newsletter

Subscribe Now

socials

Disclaimer: Any discussion of medical management options on this website is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

arrow up to top